324 Index Name Paper ref. Name Paper ref. Chu, S Wed 331 Chu, TTW FC02.4.6, Tue 140 Chua, CB Wed 194 Chua, T Mon 238 Chua, YA Mon 361 Chuang, Y-F Mon 423 Chumakov, D Tue 024 Chung, HC Mon 029 Chung, J Tue 349, Thu 418 Chung, JY Mon 013, Mon 033 Chung, YW Thu 341 Chuppa, S Mon 280 Churchill, GC Wed 268 Churin, A Tue 167 Ciaccioli, G FC18.4.5 Cianci, S Thu 440 Ciangherotti, C Thu 205 Cichutek, K PL02 Cifuentes, L Mon 014, Mon 015 Cintra, A Wed 339 Cipriano, M Tue 465 Ciric, B Tue 321 Cirillo, MC Thu 353, Wed 332, Wed 333,Wed 334 Cirino, G Thu 081, Thu 202 Cirovic, S Wed 103 Ciubotariu, D Thu 175 Clairambault, J W07.4 Clanachan, A Tue 183 Clark, AR FC09.1.5, W21.5, Tue 239 Clark, Nicolas C FC14.1.4 Clark, R Wed 270 Clarke, K FC06.3.4 Clausen, BE Wed 056 Clausen, RP FC11.5.6, Wed 084 Clavreul, N Thu 273, Thu 274 Clawson, G Mon 285 Clement, N Thu 055, Mon 161 Clemmensen, C FC11.2.6, FC11.5.1 Climent, B Mon 239, Wed 224, Wed 225 Coats, P Thu 272 Cobos-Puc, LE W13.3 Coccuzzo Sampaio, S Thu 353 Coe, JW FC14.2.3 Coelho, AL Mon 314 Coelho, M Mon 095, Mon 097, Mon 094 Cogolludo, A Mon 374, Tue 121, Wed 226, Thu 217 Cohall, D Wed 335 Cohen, A Thu 215 Cohen, AF Tue 148, FC10.4.6 Cole, W W03.7 Cole, WC Wed 239 Coll, T Wed 440 Coller, J Tue 495 Colli, E FC08.2.3 Collis, M W15.2 Coloma, P FC04.1.6 Colucci d'Amato, C Tue 488, Mon 449 Coman, O Mon 111 Coman, OA Mon 274 Combescure, C Tue 305 Comerma-Steffensen, S Tue 362 Compagnie, S Mon 232 Company, C Thu 437 Company, MA Thu 407 Compeer, MG Wed 037, Thu 208 Comps-Agrar, L FC11.2.1, FC11.3.5, Wed 077, Thu 035 Conde, MV Thu 054 Conde, S Mon 079 Conforti, A Mon 129 Cong, W Wed 336 Cong, W-H Thu 376 Cong, Y Tue 360, Conigrave, AD Wed 043 Conn, PJ FC11.5.2, FC17.2.3 Conradie, KR Thu 016 Cons, BL Wed 339 Constable, T FC14.3.3 Contreras, C Thu 249, Mon 239 Cook, JM FC03.3.3 Cooper, M FC03.3.5 Cooper, ME Thu 228 Copani, A Wed 400 Coquerel, A Thu 173, Mon 362 Corbin, JD FC08.1.5 Corcostegui, R Mon 254 Cordeddu, G Tue 133 Cornell, C Thu 088 Cornes, L W10.2 Cornish, J Wed 190 Corrao, G FC04.1.6, FC04.3.6, Tue 093 Côrrea, FMA Wed 411 Correa-Basurto, J Tue 195 Correia-de-Sá, I Wed 114 Correia-de-Sá, P FC08.2.6, Thu 064 Cortes, L FC16.2.5 Cortijo, J Thu 437 Cosic-Cerovac, N Wed 009 Cossey, V Wed 002 Costa, CA Wed 341, Wed 340 Costa, ECA Mon 010 Costa, ES Mon 273 Costa, TJ FC06.1.5 Costa-Neto, C Thu 068 Cöster, M Thu 087 Costescu, M Mon 274 Cotrim, M Wed 337 Cots, JM FC13.1.5 Coupar, I Thu 032 Couture, R Tue 275, Thu 073 Cowan, A Wed 038 Cox, J Wed 152 Coyle, JR Mon 388, Wed 170 Cracowski, J-L Wed 208, Thu 244, Thu 245 Cristante, E FC15.1.5 Cromarty, D Mon 368 Crowe, A Mon 051, Tue 063 Crown, N Tue 301 Crozier, A Thu 328 Crupi, D Wed 317 Cruz, J FC03.1.5 Cruz, MDC Wed 217 Cruz, MT Mon 291 Cruz-Machado, S Thu 204 Csajka, C FC10.5.3 Cseharovszky, R Mon 318
Name Paper ref. Name Paper ref. Csikasz, R Wed 063 Cuautle-Rodríguez, P Tue 431 Cuciureanu, M FC14.2.6, Cui, P Wed 378 Cui, R Thu 445 Cui, S-Y Mon 082 Cui, X-Y Thu 386 Cui, Y FC13.4.3 Cui, YG Thu 341 Cui, Zong Jie Wed 039 Cuíñas, A Wed 359 Cuíñas, A Wed 227 Culie, C Tue 172 Culig, J Mon 127 Cullen, W Mon 453 Culter, M Wed 013 Cumming, P FC17.1.2 Cummins, TR FC12.2.2 Cumps, J Tue 182 Cunha, F Mon 275 Cunha, FQ Tue 255 Cunha, Thiago FC03.1.5 Curnow, J Tue 233 Cury, Y Mon 273 Cury, Yara Mon 276 Cusinato, F Thu 360 Cussac, D Mon 084 Cussonneau, X Mon 193 Cuzzocrea, S FC18.1.5, FC18.3.6, Mon 277, Mon 286 D´Ocon, P Tue 165 Da Costa-Guevara, DJ Wed 040 da Cruz e Silva, O Mon 146 da Motta, NAV Wed 232 da Silva Rodrigues, E Wed 041 da Silva, AL FC16.2.3 da Silva, LL Mon 279, Wed 232 da Silva, R Wed 198, FC15.4.5 da Silva, RF Thu 061 Daali, Y Tue 166, Mon 337 D'Acunto, CW Tue 406 D'Addario, C FC14.1.5 Dadgar, FN Mon 036 Dadkhah, F FC01.3.5 D'Agostino, G FC18.1.6 Dahan, A W12.4 Dahan-Farkas, N Tue 404 Dai, H Tue 070 Dai, JM Wed 228 Dai, Y-W Wed 262 Dai, Z-K Thu 105 Daiber, A W30.3, W04.2.4 Dalhoff, K Mon 345 Dalla, C W33.4 Dalli, J FC09.5.7, FC09.4.6 Dalodom, T Wed 338 Dalsgaard, T Wed 229, Wed 230, Wed 281, Wed 282, Thu 259 Dalton, GD Wed 029 Daly, AK FC13.3.2 Daly, C Thu 030 Daly, CJ W01.2.2 Dam, E W26.4 Dambrova, M Tue 141 Damchi Jelodar, J Thu 412 Damkier, P FC04.4.2, Mon 050, Tue 395, Damsgaard, EM Mon 142 Damsgaard, J Wed 160 Danchin, N Mon 145, Mon 132 Dandara, C Thu 016 Daniel, H FC02.3.3 Danielyan, L YI.02 Danscher, G Mon 320 Danser, J Wed 292, Wed 220 Dantas, AP YI.03, Thu 225 Dantas, R Wed 131 Darabi, M Tue 164 D'Arrigo, C Thu 419 Darrouzain, F Mon 363 Darsova, D Tue 445 Darvas, F Tue 130 Darwish, IE Mon 364, Tue 464 Darwish, SA Mon 364 Darýverenli, E Wed 357 Das, A Mon 314 Das, M Thu 427 Daulat, A Thu 055, Wed 072 Daulat, AM Thu 028 Dautreaux, B Thu 242 Davarian, A Mon 196 Davel, AP Wed 042, Wed 231 Davenport, AP W14.1, Tue 479 Davey, AE Wed 043, Wed 089 Davids, H Mon 308, Tue 404 Davidson, C Wed 425, Mon 195, Mon 430 Davidson, M SS01.1 D'Avolio, A Tue 405 Davy, J-M FC06.2.3 Davydova, KS Thu 253 Dawson, J FC15.1.6 Dawson, N FC17.1.4 Dayer, P Tue 166, Tue 305, Mon 337 de Almeida, RB Wed 395 de Andrade Cavalcante, F Thu 351 de Andrade, GM Tue 282 de Araujo, I W02.1.6 de Basilio, V Tue 362 de Bock, M Thu 237 de Brito Gariépy, H Tue 275 de Brito, FCF Wed 232 de Bruin, ML FC04.3.3 de Carvalho, AGG Tue 281 de Carvalho, MHC Wed 233 de Cock, J FC03.2.6 de Cock, P Mon 365, Tue 306 de Diego, AMG FC12.1.6, FC16.2.5 de Esch, I Thu 060 de Fátima, A Mon 097 de Filippis, D FC18.4.6, Tue 465 de Francia, S Tue 405, Wed 010 de Franco, F FC18.4.5 de Graaf, C Thu 082 de Jesus Barreiro, E Mon 279 de Jesús, ML Wed 046 de Jesus, S Thu 254 de Jong-van den Berg, LTW FC04.4.4 Index 325
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277: FC17 New approaches and targets in
- Page 278 and 279: FC17 New approaches and targets in
- Page 280 and 281: W34 State-of-the-art of basic and c
- Page 282 and 283: FC10 Drugs for half the world: Paed
- Page 284 and 285: FC11 G protein-coupled 7TM receptor
- Page 286 and 287: FC11 G protein-coupled 7TM receptor
- Page 288 and 289: FC11 G protein-coupled 7TM receptor
- Page 290 and 291: FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377:
374 Index Name Paper ref. Name Pape
- Page 378 and 379:
376 Index Name Paper ref. Name Pape
- Page 380 and 381:
378 Index Name Paper ref. Name Pape
- Page 382 and 383:
380 Index Name Paper ref. Name Pape
- Page 384 and 385:
382 Notes Notes
- Page 386:
Final Programme printed in Singapor